Role of Different Replacement Fluids During Extracorporeal Treatment in a Pig Model of Sepsis
Corresponding Author
Martin Sauer
Departments of Anesthesiology and Intensive Care Medicine
Dr Martin Sauer, Physician, Department of Anesthesiology and Intensive Care Medicine, University of Rostock, Schillingallee 35, 18057 Rostock, Germany. Email: [email protected]Search for more papers by this authorJens Altrichter
Division of Nephrology, Department of Medicine, Medical Faculty of the University of Rostock, University of Rostock, Rostock
Search for more papers by this authorThomas Mencke
Departments of Anesthesiology and Intensive Care Medicine
Search for more papers by this authorSven Klöhr
Department of Anesthesiology, Hospital Bamberg, Bamberg, Germany
Search for more papers by this authorMaren Thomsen
Departments of Anesthesiology and Intensive Care Medicine
Search for more papers by this authorGabriele Nöldge-Schomburg
Departments of Anesthesiology and Intensive Care Medicine
Search for more papers by this authorSteffen R. Mitzner
Division of Nephrology, Department of Medicine, Medical Faculty of the University of Rostock, University of Rostock, Rostock
Search for more papers by this authorCorresponding Author
Martin Sauer
Departments of Anesthesiology and Intensive Care Medicine
Dr Martin Sauer, Physician, Department of Anesthesiology and Intensive Care Medicine, University of Rostock, Schillingallee 35, 18057 Rostock, Germany. Email: [email protected]Search for more papers by this authorJens Altrichter
Division of Nephrology, Department of Medicine, Medical Faculty of the University of Rostock, University of Rostock, Rostock
Search for more papers by this authorThomas Mencke
Departments of Anesthesiology and Intensive Care Medicine
Search for more papers by this authorSven Klöhr
Department of Anesthesiology, Hospital Bamberg, Bamberg, Germany
Search for more papers by this authorMaren Thomsen
Departments of Anesthesiology and Intensive Care Medicine
Search for more papers by this authorGabriele Nöldge-Schomburg
Departments of Anesthesiology and Intensive Care Medicine
Search for more papers by this authorSteffen R. Mitzner
Division of Nephrology, Department of Medicine, Medical Faculty of the University of Rostock, University of Rostock, Rostock
Search for more papers by this authorAbstract
In an extracorporeal combination therapy, the impact of different replacement fluids on survival was tested in a bacterial sepsis model in pigs. In an animal study 19 pigs, weighing 7.5–11.1 kg, were included. All groups received an intravenous lethal dose of live Staphylococcus aureus over 1 h. The animals were treated by an extracorporeal circuit consisting of online centrifugation and subsequent plasma filtration for 4 h. The extracorporeal circuit was pre-filled with 400 mL replacement fluid. In the P0 group 100% hydroxyethyl starch 130/0.4 was used as replacement fluid; in the P30 group 30% pig plasma and 70% hydroxyethyl starch; and in the P100 group 100% pig plasma. The observation time was 7 days. All animals of the group P100 survived, while all animals of group P0 and five out of seven animals of the P30 group died during the observation time. Extracorporeal therapy consisting of online centrifugation and plasma filtration with 100% pig plasma as replacement fluid significantly improved survival in a pig model of sepsis. Further studies with this approach are encouraged.
REFERENCES
- 1 Angus DC, Linde-Zwirble WT, Lidicker J et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303–10.
- 2 Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign. International guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 36: 296–327.
- 3 Rivers E, Nguyen B, Havstad S et al. Early Goal-Directed Therapy Collaborative Group. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368–77.
- 4 Ronco C, Tetta C, Mariano F et al. Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 2003; 27: 792–801.
- 5 Rimmelé T, Kellum JA. Clinical review: blood purification for sepsis. Crit Care 2011; 15: 205.
- 6 Busund R, Koukline V, Utrobin U et al. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial. Intensive Care Med 2002; 28: 1434–9.
- 7 Iwai H, Nakaki M, Naito T et al. Removal of endotoxin and cytokines by plasma exchange in patients with acute hepatic failure. Crit Care Med 1998; 26: 873–6.
- 8 Van Deuren M, Frieling JT, van der Ven-Jongekrijg J et al. Plasma patterns of tumor necrosis factor-alpha (TNF) and TNF soluble receptors during acute meningococcal infections and the effects of plasma exchange. Clin Infect Dis 1998; 26: 918–23.
- 9 Stegmayr BG, Banga R, Berggren L et al. Plasma exchange as rescue therapy in multiple organ failure including acute renal failure. Crit Care Med 2003; 31: 1730–6.
- 10 Sauer M, Altrichter A, Mencke T et al. Plasma separation by centrifugation and subsequent plasma filtration: impact on survival in a pig model of sepsis. Ther Apher Dial 2012; 16: 205–12.
- 11 Lee PA, Weger GW, Pryor RW et al. Effects of filter pore-size on efficacy of continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicaemia in immature swine. Crit Care Med 1998; 26: 730–7.
- 12 Lee PA, Matson JR, Pryor RW, Hinshaw LB. Continuous arteriovenous hemofiltration therapy for Staphylococcus aureus-induced septicemia in immature swine. Crit Care Med 1993; 21: 914–24.
- 13 Hinshaw LB, Taylor FB, Chang ACK et al. Staphylococcus aureus-induced shock: a pathophysiologic study. Circ Shock 1988; 26: 257–65.
- 14 Ronco C, Inguaggiato P, D'Intini V et al. The role of extracorporeal therapies in sepsis. J Nephrol 2003; 16: 34–41.
- 15 Bellomo R, Honoré PM, Matson J et al. Extracorporeal blood treatment (EBT) methods in SIRS/Sepsis. Int J Artif Organs 2005; 28: 450–8.
- 16 Cole L, Bellomo R, Hart G et al. A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med 2002; 30: 100–6.
- 17 Payen D, Mateo J, Cavaillon JM et al. Impact of continuous venovenous hemofiltration on organ failure during the early phase of severe sepsis: a randomized controlled trial. Crit Care Med 2009; 37: 803–10.
- 18 Sykora R, Chvojka J, Krouzecky A et al. Coupled plasma filtration adsorption in experimental peritonitis-induced septic shock. Shock 2009; 31: 473–80.
- 19 Eguchi Y. Plasma dia-filtration for severe sepsis. Contrib Nephrol 2010; 166: 142–9.
- 20 Reeves JH, Butt WW, Shann F et al. Continuous plasmafiltration in sepsis syndrome. Plasmafiltration in Sepsis Study Group. Crit Care Med 1999; 27: 2096–104.
- 21 Levy H, Ash SR, Knab W et al. Systemic inflammatory response syndrome treatment by powdered sorbent apheresis: the biologic-detoxification plasma filtration system. ASAIO J 1998; 44: M659–65.
- 22 Ronco C, Brendolan A, Lonneman G et al. A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 2002; 30: 1250–5.
- 23 Korach JM, Berger P, Giraud C, Le Perff-Desmann C, Chillet P. Role of replacement fluids in the immediate complications of plasma exchange. Intensive Care Med 1998; 24: 452–8.
- 24
Brecher ME,
Owen HG,
Bandarenko N.
Alternatives to albumin: starch replacement for plasma exchange.
J Clin Apher
1997; 12: 146–53.
10.1002/(SICI)1098-1101(1997)12:3<146::AID-JCA8>3.0.CO;2-A CAS PubMed Web of Science® Google Scholar
- 25 Arslan Ö, Arat M, Tek I, Ayyildiz E, Ilhan O. Therapeutic plasma exchange in a single center: Ibni Sina experience. Transfus Apher Sci 2004; 30: 181–4.
- 26
Perel P,
Roberts I.
Colloids versus crystalloids for fluid resuscitation in critically ill patients.
Cochrane Database Syst Rev
2007; CD:000567.
10.1002/14651858.CD000567.pub3 Google Scholar
- 27 Brunkhorst FM, Engel C, Bloos F et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008; 358: 125–39.
- 28 de Jonge E, Levi M. Effects of different plasma substitutes on blood coagulation: a comparative review. Crit Care Med 2001; 29: 1261–7.
- 29 Schortgen F, Lacherade JC, Bruneel F et al. Effects of hydroxyethylstarch and gelatine on renal function in severe sepsis: a multicentre randomized study. Lancet 2001; 357: 911–16.
- 30 Dart AB, Mutter TC, Ruth CA et al. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev 2010; CD:0007594.
- 31 Franz A, Braunlich P, Gamsjager T et al. The effects of hydroxyethyl starches of varying molecular weights on platelet function. Anesth Analg 2001; 92: 1402–7.
- 32 de Jonge E, Levi M, Buller HR. Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects. Intensive Care Med 2001; 27: 1825–9.
- 33 Innerhofer P, Fries D, Markreiter J et al. The effects of perioperatively administered colloids and crystalloids on primary platelet-mediated hemostasis and clot formation. Anesth Analg 2002; 95: 858–65.
- 34 Nielsen VG. Hemodilution modulates the time of onset and rate of fibrinolyses in human and rabbit plasma. J Heart Lung Transplant 2006; 25: 1344–52.
- 35 Fumeaux T, Pugin J. Role of interleukin-10 in the intracellular sequestration of human leukocyte antigen-DR in monocytes during septic shock. Am J Respir Crit Care Med 2002; 166: 1475–82.
- 36 Guignant C, Lepape A, Huang X et al. Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfuctions in septic shock patients. Crit Care 2011; 15: R99.
Citing Literature
